Rocket Pharmaceuticals, Inc. (RCKT) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -191.64M USD | Operating Income (Loss) |
| Revenue | 0.00 USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 124.37M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-191.64M | $0.00 | (m) | $124.37M | (m) | (m) |
| 2026-03-31 | $-215.87M | $0.00 | (m) | $137.53M | (m) | (m) |
| 2025-12-31 | $-231.75M | $0.00 | (m) | $142.01M | (m) | (m) |
| 2025-09-30 | $-250.48M | $0.00 | (m) | $150.03M | (m) | (m) |
| 2025-06-30 | $-267.65M | $0.00 | (m) | $158.27M | (m) | (m) |
| 2025-03-31 | $-270.22M | $0.00 | (m) | $161.96M | (m) | (m) |
| 2024-12-31 | $-273.20M | $0.00 | (m) | $171.24M | (m) | (m) |
| 2024-09-30 | $-273.79M | $0.00 | (m) | $175.63M | (m) | (m) |
| 2024-06-30 | $-269.80M | $0.00 | (m) | $180.16M | (m) | (m) |
| 2024-03-31 | $-264.84M | $0.00 | (m) | $185.20M | (m) | (m) |
| 2023-12-31 | $-259.66M | $0.00 | (m) | $186.34M | (m) | (m) |
| 2023-09-30 | $-265.46M | $0.00 | (m) | $194.63M | (m) | (m) |
| 2023-06-30 | $-258.52M | $0.00 | (m) | $191.17M | (m) | (m) |
| 2023-03-31 | $-243.97M | $0.00 | (m) | $181.15M | (m) | (m) |
| 2022-12-31 | $-224.34M | $0.00 | (m) | $165.57M | (m) | (m) |
| 2022-09-30 | $-199.59M | $0.00 | (m) | $148.55M | (m) | (m) |
| 2022-06-30 | $-190.75M | $0.00 | (m) | $144.79M | (m) | (m) |
| 2022-03-31 | $-170.59M | $0.00 | (m) | $127.96M | (m) | (m) |
| 2021-12-31 | $-167.25M | $0.00 | (m) | $125.48M | (m) | (m) |
| 2021-09-30 | $-182.15M | $0.00 | (m) | $144.35M | (m) | (m) |
| 2021-06-30 | $-159.90M | $0.00 | (m) | $126.03M | (m) | (m) |
| 2021-03-31 | $-149.41M | $0.00 | (m) | $117.97M | (m) | (m) |
| 2020-12-31 | $-134.30M | $0.00 | (m) | $106.38M | (m) | (m) |
| 2020-09-30 | $-94.71M | $0.00 | (m) | $70.01M | (m) | (m) |
| 2020-06-30 | $-86.49M | $0.00 | (m) | $63.18M | (m) | (m) |
| 2020-03-31 | $-81.33M | $0.00 | (m) | $60.44M | (m) | (m) |
| 2019-12-31 | $-76.15M | $0.00 | (m) | $58.62M | (m) | (m) |
| 2019-09-30 | $-83.05M | $0.00 | (m) | $67.64M | (m) | (m) |
| 2019-06-30 | $-79.22M | $0.00 | (m) | $65.87M | (m) | (m) |
| 2019-03-31 | $-75.70M | $0.00 | (m) | $62.66M | (m) | (m) |
| 2018-12-31 | $-71.16M | $0.00 | (m) | $53.27M | (m) | (m) |
| 2018-09-30 | $-58.23M | (m) | (m) | $33.78M | (m) | (m) |
| 2018-06-30 | $-49.62M | (m) | (m) | $25.61M | (m) | (m) |
| 2018-03-31 | $-38.27M | (m) | (m) | $17.65M | (m) | (m) |
| 2017-12-31 | $-26.74M | (m) | (m) | $14.19M | (m) | (m) |
| 2017-09-30 | $-34.77M | (m) | (m) | $23.03M | (m) | (m) |
| 2017-06-30 | $-38.78M | (m) | (m) | $28.63M | (m) | (m) |
| 2017-03-31 | $-41.71M | (m) | (m) | $31.47M | (m) | (m) |
| 2016-12-31 | $-41.88M | (m) | (m) | $31.98M | (m) | (m) |
| 2016-09-30 | $-37.87M | (m) | (m) | $28.41M | (m) | (m) |
| 2016-06-30 | $-32.58M | (m) | (m) | $23.61M | (m) | (m) |
| 2016-03-31 | $-27.48M | (m) | (m) | $19.10M | (m) | (m) |
| 2015-12-31 | $-20.40M | (m) | (m) | $12.55M | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $-7.70M | (m) | (m) | $5.59M | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |